Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 7/20 | 0.58 |
| ▸ | CA2 | P00918 | 7/20 | 0.58 |
| ▸ | CA1 | P00915 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | STAT3 | P40763 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.46 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | USP7 | Q93009 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4236217 | 0.83 | CA9 (0.58) | CA9CA2CA1MEN1KMT2A | |
| SCHEMBL1371709 | 0.75 | CA2 (0.53) | CA9CA2CA1MEN1KMT2A | |
| SCHEMBL4515208 | 0.75 | CA9 (0.38) | CA9CA2CA1MEN1KMT2A | |
| SCHEMBL31028807 | 0.75 | CA2 (0.53) | CA9CA2CA1MEN1KMT2A | |
| SCHEMBL7610058 | 0.75 | CA2 (0.53) | CA9CA2CA1MEN1KMT2A | |
| SCHEMBL7148444 | 0.75 | CA9 (0.53) | CA9CA2CA1MEN1KMT2A | |
| SCHEMBL13261334 | 0.75 | CA2 (0.53) | CA9CA2CA1MEN1KMT2A | |
| SCHEMBL10371873 | 0.75 | CA2 (0.53) | CA9CA2CA1MEN1KMT2A | |
| SCHEMBL7130486 | 0.75 | CA2 (0.53) | CA9CA2CA1MEN1KMT2A | |
| SCHEMBL8024075 | 0.73 | CA1 (1.00) | CA9CA2CA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6555555-B1 | Inhibitors of interleukin-6 and/or interleukin-12; for example 4,5-dimethyl-1,1-dioxidebenzo(b)thiophene; treating various inflammatory diseases, autoimmune diseases, cancer, osteoporosis | ONO PHARMACEUTICAL CO., LTD. (JP) | 2003-04-29 | — | — | US | claimed |
| US-20030073706-A1 | Fused thiophone derivatives and drugs containing the same as the active ingredient | KONISHI MIKIO (JP) | 2003-04-17 | — | — | US | claimed |
| US-6420391-B1 | PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S | ONO PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | claimed |
| EP-1067128-A1 | FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-10 | — | — | EP | claimed |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | DUKE UNIVERSITY | 2024-09-26 | — | — | US | disclosed |
| US-20230212568-A1 | MICRORNA-MEDIATED METHODS FOR REJUVENATING CNS GLIAL POPULATIONS | UNIVERSITY OF ROCHESTER | 2023-07-06 | — | — | US | disclosed |
| WO-2023068852-A1 | BENZOTHIOPHENE-1,1-DIOXIDE DERIVATIVE COMPOUND AS STAT3 INHIBITOR, AND USE THEREOF | 주식회사 프롬바이오 | 2023-04-27 | — | — | WO | disclosed |
| WO-2022199589-A1 | PYRIMIDINE DERIVATIVES | 南京明德新药研发有限公司 | 2022-09-29 | — | — | WO | disclosed |
| US-11273154-B2 | Azole compounds as ubiquitin-specific protease USP7 inhibitors | PROGENRA, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| EP-2930170-B1 | PYRIDONE COMPOUND FOR USE IN THE TREATMENT OF DERMATOLOGICAL DISORDERS | KYOWA KIRIN CO LTD (JP) | 2020-02-05 | — | — | EP | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| EP-0944590-B1 | AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS | DIMENSIONAL PHARM INC (US) | 2002-03-20 | — | — | EP | disclosed |
| EP-1183229-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-03-06 | — | — | EP | disclosed |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-11-01 | — | — | US | disclosed |
| US-6288082-B1 | COMPOUNDS SUCH AS 6,7-DIETHOXY-4-(INDAN-5-YLAMINO) -QUINOLINE-3-CARBONITRILE USED AS ANTINEOPLASTIC AGENTS AND IN THE TREATMENT OF POLYCYCSTIC KIDNEY DISEASE | AMERICAN CYANAMID COMPANY | 2001-09-11 | — | — | US | disclosed |
| US-6235778-B1 | ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-05-22 | — | — | US | disclosed |
| EP-1067128-A1 | FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-10 | — | — | EP | disclosed |
| WO-2000069810-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-11-23 | — | — | WO | disclosed |
| WO-2000063202-A2 | BENZO[b] THIOPHENE SULFONAMIDE-1, 1-DIOXIDE DERIVATIVES AND THEIR USE AS ANTINEOPLASTIC AGENTS | UNIVERSIDAD PUBLICA DE NAVARRA (ES) | 2000-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273154-B2 | Azole compounds as ubiquitin-specific protease USP7 inhibitors | USP7, USP1, USP2 | CA9 729/4885CA2 2267/4885CA1 773/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | CA9 4738/4885CA2 3513/4885CA1 4834/4885 |
| US-20230212568-A1 | MICRORNA-MEDIATED METHODS FOR REJUVENATING CNS GLIAL POPULATIONS | MYT1, STAT3, MYC | CA9 4476/4885CA2 4441/4885CA1 4369/4885 |
| US-20010037039-A1 | Aminoguanidines and alkoxyguanidines as protease inhibitors | F9, PLG, MMP9 | CA9 173/4885CA2 1722/4885CA1 1780/4885 |
| US-20030073706-A1 | Fused thiophone derivatives and drugs containing the same as the active ingredient | TPMT, CD47, THPO | CA9 3056/4885CA2 3155/4885CA1 2040/4885 |
| US-20240317727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | HSF1, HSP90AB1, HSP90AA1 | CA9 3532/4885CA2 2575/4885CA1 2512/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | CA9 4678/4885CA2 3360/4885CA1 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.